Alex Sverdlov has worked as a statistical scientist in the biopharmaceutical industry since 2007, in such companies as Novartis, Merck Serono and Bristol-Myers Squibb. He has handled clinical trials in neurodegenerative diseases, metabolic disorders, ophthalmology, immunology, and oncology. Alex has been involved in active research on adaptive designs for clinical trials to improve efficiency of drug development. He recently edited a book ‘Modern Adaptive Randomized Clinical Trials: Statistical and Practical
Aspects’ which was published by CRC Press in 2015. Alex holds a Ph.D. in statistical science from George Mason University.